Comments
Commented by Fabian Lorenz on August 25th, 2025 | 07:10 CEST
Massive UNDERVALUATION?! Bayer, SFC Energy, Veganz Group
Massive undervaluation of Veganz shares? The transformation from a vegan food supplier to a foodtech company is increasingly taking shape. The first shipment of oat milk, produced using a revolutionary process, is about to be delivered to the US, and analysts see EUR 160 million in revenue potential. The real question is: When will the target price and the share price rise? Bayer shares have risen surprisingly strongly this year. Investors have largely ignored problem areas. But now a rating agency is pointing out the weaknesses, and analysts remain cautious. Investors were bullish on SFC Energy. Then came the forecast adjustment, and the share price plummeted. Now, a multi-million euro order is helping to stabilize the situation.
Read
Commented by Nico Popp on August 25th, 2025 | 07:05 CEST
New research findings – Cell metabolism relevant in cancer: Roche, Novartis, and Vidac Pharma
What if cancer cells no longer grew uncontrollably, and we could target the metabolism of these cells directly? The so-called Warburg effect makes this possible. Discovered around 100 years ago by Otto Warburg, the effect describes the energy metabolism of cancer cells and shows that their metabolism differs from that of healthy cells. This opens up great opportunities for specific therapies in biotechnology. The theoretical assumption is that if the metabolism of cancer cells can be specifically disrupted, treatment will be targeted and free of side effects. Biotech start-up Vidac Pharma is fully committed to the Warburg effect. We explain what the Canadians are researching and why the technology could complement the offerings of several large pharmaceutical companies.
Read
Commented by André Will-Laudien on August 25th, 2025 | 07:00 CEST
100% with NATO contracts from the air! Airbus, Globex Mining, Boeing, and Lufthansa
The craziness continues! NATO member states have agreed on new planning targets for armaments and capabilities and, according to Secretary General Mark Rutte, have increased the requirements for air and missile defense by about 30%. Rutte stated: "We need more resources, troops, and capabilities to be prepared for any threat." German Chancellor Friedrich Merz emphasised that Germany would provide all the necessary resources to expand the Bundeswehr into the strongest conventional army in Europe. According to experts, large-scale defense projects, particularly in the aerospace sector, will require enormous investments and far-reaching acquisitions. Across Europe, around EUR 300 billion is expected to be invested in air forces by 2030. Investors should now set the course to benefit from the flood of orders in the aerospace sector.
Read
Commented by Nico Popp on August 22nd, 2025 | 07:10 CEST
Gold story remains intact – Three good ideas for every portfolio: Dryden Gold, Kinross Gold, and Barrick Mining
"Gold is money. Everything else is credit" – banker JP Morgan recognized this long ago. The precious metal is currently in high demand again. ETF investors in particular, but also central banks, are betting on gold. In July, global holdings in ETFs climbed to 3,639 tons, the highest level since August 2022. Central banks have purchased around 1,000 tons of gold annually over the past three years – about twice the amount they bought per year in the previous decade. This shows that demand from both private and professional investors remains unbroken. We present three promising gold stocks and explain where even speculative investors can get their money's worth.
Read
Commented by Fabian Lorenz on August 22nd, 2025 | 07:05 CEST
EXCITEMENT at RENK and Power Metallic Mines! Sell SMA Solar shares now?
Power Metallic Mines shares have risen by around 30% in recent weeks. According to the CEO, however, this is likely to be just the beginning. Operational progress in developing the world-class multi-metal project discovered last year could lead to a dynamic turn by the end of the year. Perhaps last year's 200% gain will even be repeated? RENK shares have gained over 200% in the current year alone. To ensure long-term success, the gearbox specialist aims to expand its business model and offer smaller autonomous tanks, among other things, in the future. SMA Solar shares have performed surprisingly well this year. Can the rally continue, or will the skeptical analysts ultimately be proven right?
Read
Commented by Nico Popp on August 22nd, 2025 | 07:00 CEST
Raw materials as the key to greater value creation: SQM, Lynas Rare Earths, Almonty Industries
Equality is a social construct. Reality, however, is diverse. This also means that some companies are in a much better starting position than others. In free markets, companies compete for market leadership and thus spur each other on to become better. However, some companies are in pole position for a variety of reasons and also have a few extra horsepower than their competitors. We use the examples of lithium specialist SQM, rare earths company Lynas Rare Earths, and innovative tungsten specialist Almonty Industries to explain which characteristics promise long-term advantages for companies and how investors can benefit.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:20 CEST
Defense sell-off – New doublers are emerging with thyssenkrupp, Almonty, and Heidelberger Druck
What defense speculators always feared as a looming threat is now happening within just one week: Peace negotiations between Russia and Ukraine! Even though nothing concrete has happened yet, the sentiment is clear: If only half of the numerous geopolitical conflicts calm down or even disappear entirely, the pressure to rearm will ease, and potential orders, which were already reflected extensively in share prices, could be reduced or canceled altogether. Public budgets resemble a pressure cooker at 120 degrees, so any relief is welcome. It will be interesting to see how far defense stocks might fall, especially after rising by up to 2000% in the case of Rheinmetall. Almonty remains interesting because, even with reduced defense demand, critical metals remain the bottleneck of Western industries. It is worth taking a closer look.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:15 CEST
High-tech correction! A brief pause, then the party continues at Palantir, Deutsche Telekom, MiMedia, and SAP
Oops – there it is. The first correction at Palantir was somewhat severe. But after a 1000% increase in 24 months – who cares? The blockbuster themes of artificial intelligence, cloud computing, and big data continue to dominate the stock market, leading to significant daily price gains. Investors seem to view the capital markets as an almost one-way success story in which valuations play hardly any role. Europe is increasingly taking the lead, with the EURO STOXX 50 rising by around 20% since the tariff dip in April. Despite apparent risks, many investors are sticking to the bull market, although the S&P 500's high Shiller P/E ratio of over 38 is sending out a clear warning signal. Deutsche Telekom is generating excitement with the announcement of another innovation push in the form of its first AI-based smartphone. The coming weeks therefore offer exciting opportunities for investors who, despite the warning signs, are betting on the continued momentum of the market. Where to invest?
Read
Commented by Armin Schulz on August 21st, 2025 | 07:10 CEST
Overvaluations in pharma and biotech reduced – Novo Nordisk, BioNxt Solutions, and Bayer are NOW in focus
Following the drastic market correction since the waning of the COVID-19 pandemic, the pharma and biotech sectors now offer more rationalized valuations and real opportunities. Instead of speculative hype, solid pipelines, clinical results, and disruptive technologies are what count today. Artificial intelligence is revolutionizing drug development, accelerating processes, and creating measurable competitive advantages. This new reality makes companies that are mastering their digital transformation particularly promising candidates. However, it is important to take a close look at each company. That is why we are examining three exciting companies today where there is a lot going on: Novo Nordisk, BioNxt Solutions, and Bayer.
Read
Commented by André Will-Laudien on August 21st, 2025 | 07:05 CEST
The AI revolution is turning biotech into a gold mine! BioNTech, Eli Lilly, NetraMark Holdings, and Pfizer know how!
Artificial intelligence (AI) is becoming increasingly important in drug research and is revolutionizing the development of new active ingredients. Machine learning and neural networks enable large amounts of data to be analyzed and potential drugs to be identified more quickly. AI also plays a central role in the planning and execution of clinical trials by recognizing data patterns, identifying suitable patients, and thus increasing the chances of success. The market for AI in drug development is growing rapidly. Experts estimate it will reach several billion US dollars by 2025, with projected annual growth of over 40%. Where are the opportunities and risks for agile investors?
Read